We are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam. With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2023-09-18 13:16:272023-09-18 15:24:46AlgiPharma Presenting at the Lipid Nanoparticle Development Europe Summit
We are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market. Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2023-08-25 15:15:272023-09-18 15:28:37AlgiPharma announces the appointment of Dr. Preston W. Campbell MD to the Board
AlgiPharma attended the LNP Formulation & Process Development conference in Boston, MA (17-19th April). Chief Scientific Officer Dr. Philip Rye presented AlgiPharma’s novel alginate oligosaccharide technology for overcoming inhalation barriers for LNP delivered therapeutics. His presentation highlighted the benefits and challenges associated with the inhalation delivery route, and how AlgiPharma’s technology can mediate the effective […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2023-04-26 13:06:322023-09-18 15:29:34AlgiPharma presented at Lipid Nanoparticle Summit in Boston
We are extremely pleased to announce the appointment of two experienced and high-calibre pharmaceutical experts to the AlgiPharma Board as non-executive Board Members. Their combined expertise will be invaluable in bringing AlgiPharma’s alginate technology closer to market. Dr Charles Johnson is an independent consultant with over 30 years’ experience in the biotechnology industry. He gained […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2023-04-26 12:45:102023-09-18 15:30:33AlgiPharma announces the appointment of Dr. Charles A Johnson and Mr. Mike Walters to the Board
AlgiPharma welcomes Mr Ole Tobias Fevang to the AlgiPharma team as accounting manager in support of the Norwegian operations. He has a master’s degree in finance from BI Norwegian Business School. He has previously worked at Norwegian banks (DNB Bank AS and Sparebanken Øst), and more recently four years as an accountant at the international […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2023-03-29 16:56:062023-08-09 17:02:37AlgiPharma Welcomes a New Member to the Team
AlgiPharma attends and presents data on its alginate oligosaccharide technology platform at the Lipid Nanoparticles Development Summit 18th-20th October in London. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2022-10-01 12:32:472023-08-09 17:02:38AlgiPharma Attends the LNP Summit Congress in London
AlgiPharma was recently granted patent protection for its United States Patent No. 11413306 (15/766272) National Phase of PCT Application PCT/EP2016/073931 for “Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract”. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded […]
AlgiPharma attends the annual ECFS congress in Rotterdam, continuing to support and learn about new developments for the treatment of people with Cystic Fibrosis. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2022-06-01 12:33:482023-08-09 17:02:38AlgiPharma Attends Annual European Cystic Fibrosis Congress in Rotterdam
AlgiPharma was recently granted patent protection in its ongoing National Phase of PCT Application PCT/EP2017/076926 for “Bacitracin-alginate oligomer conjugates”. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the […]
AlgiPharma was recently granted patent protection for its European Patent No. 3528830 (17791037.9) Polymyxin-alginate oligomer conjugates. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology […]
AlgiPharma’s collaboration partners in Cardiff University have recently published an article on the potentiating effects of AlgiPharma’s alginate oligosaccharide technology: Stokniene J, Varache M, Rye PD, Hill KE, Thomas DW, Ferguson EL. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Sci Rep. 2022 Mar 23;12(1):4986. doi: 10.1038/s41598-022-08927-1. PMID: 35322119; PMCID: […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2022-03-01 12:16:452023-08-09 17:02:39AlgiPharma Study Published on Potentiation of Colistin.
AlgiPharma in collaboration with its clinical trials team for the randomized clinical trial NCT02453789 in CF has recently been published: Fischer R, Schwarz C, Weiser R, Mahenthiralingam E, Smerud K, Meland N, Flaten H, Rye PD. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros. […]
January 27th 2022 AlgiPharma was featured in DelveInsights’s “Cystic Fibrosis Pipeline Insight, 2022” report that provides insight on company and pipeline activities in the Cystic Fibrosis therapeutics landscape. The report highlights around 60+ products under development by companies working on novel opportunities that could influence Cystic Fibrosis treatment. The report provides insights into different therapeutic […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2022-01-27 11:56:552023-08-09 17:02:40AlgiPharma in the News: GlobalNewswire and DelveInsight’s Business Report.
AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Councils Innovation Project for the Industrial Sector program for the project “Therapeutic Alginates for Resistant and Recurrent Infections: Generating Eradication Therapies (TARRGET)”. The project grant awarded from the Research Council combined with the Norwegian government tax incentive scheme (SkatteFUNN) results in a […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2021-12-20 09:27:472023-08-09 17:02:41AlgiPharma secures 22 MNOK in non-dilutive funding for development of its antimicrobial alginate oligosaccharide technology, with the goal to enhance fighting multidrug resistance.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2020-10-06 09:47:072023-08-09 17:02:41AlgiPharma awarded 16 MNOK grant from the Norwegian Research Council’s Innovation Project for the Industrial Sector program.
Director Clinical Research / Chief Medical Officer AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. The deadline for applications is the 24th May 2020 (see links below for further details). More details can be found at: – www.borka.no/jobb/director-clinical-research-chief-medical-officer/ – www.finn.no/177948590 – www.linkedin.com/groups/2085624 – […]
AlgiPharma AS acquired by AlgiPharma AB On December 20, 2019 the Swedish AlgiPharma AB finalized the acquisition of the Norwegian AlgiPharma AS. All shareholders in AlgiPharma AS accepted the offer from AlgiPharma AB which means that the shareholders have the same number of shares and ownership percentage in the new parent company AlgiPharma AB as […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2020-01-22 13:37:222023-08-09 17:02:42New parent company in the AlgiPharma group
AlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO) Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish […]
AlgiPharma announces two new positions avaliable. AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway. The deadline for applications is the 12th May 2019 […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2019-04-30 10:55:412023-08-09 17:02:42AlgiPharma is Recruiting
New Phase 2b Clinical Trial: A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205) A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2019-04-30 10:18:382023-08-09 17:02:43New 2b Clinical Trial started in Australia
AlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand. About Cystic Fibrosis: Cystic […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2019-01-01 10:43:382023-08-09 17:02:44AlgiPharma Appoints Director for Australian Operations
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2018-12-07 22:14:332023-08-09 17:02:44Innovation Award Winner for 2018
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2018-11-21 10:11:192023-08-09 17:05:10AlgiPharma registers new company in Australia
An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2018-01-15 16:09:232023-08-09 17:05:11AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme
AlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2018-01-15 15:42:412023-08-09 17:05:11AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)
AlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2018-01-15 15:19:032023-08-09 17:05:12AlgiPharma awarded 4 year grant from the Norwegian Research Council’s NANO2021 programme
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2017-06-28 00:10:352023-08-09 17:05:12AlgiPharma collaboration with Cardiff University wins Medical Innovation Award
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2016-06-03 15:00:592023-08-09 17:05:13AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2016-05-04 12:03:102023-08-09 17:05:13AlgiPharma features in CFF drug development pipeline
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00Philip Ryehttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngPhilip Rye2016-02-24 12:31:392023-08-09 17:05:14AlgiPharma granted Orphan Drug designation by FDA
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2015-02-20 15:05:142023-08-09 17:05:15AlgiPharma starts two new Phase 2b trials in Cystic Fibrosis
AlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2015-02-12 15:03:482023-08-09 17:05:15AlgiPharma awarded four year grant from Norwegian Research Council
Building on the previous success with the AlgiFerm project, AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), FMC Biopolymer, and SINTEF have secured additional funding from the UK’s Technology Strategy Board (now Innovate UK) and Innovation Norway for further investigation on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. The study will focus on developing methods for scaling-up microbial fermentation production of OligoG at CPI.
The collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has been successful in achieving the project milestones.
AlgiPharma has been awarded a four year grant from the Norwegian Research Council for the project “Tailored OligoG in the treatment of chronic infectious biofilms”.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2013-07-19 15:01:132023-08-09 17:05:16AlgiPharma awarded four year grant from Norwegian Research Council
A collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has secured funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for a feasibility study on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG.
Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, Onsøyen E, Myrvold R, Hill KE, Thomas DW. Biofouling. 2013 Apr;29(4):413-21. doi: 10.1080/08927014.2013.777954. External link to Pubmed.gov Abstract The influence of a novel, safe antibiofilm therapy on the mechanical properties of Pseudomonas aeruginosa and Acinetobacter baumannii biofilms in vitro was characterized. A multiscale approach employing […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2013-04-16 14:57:422023-08-09 17:05:17The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms
In collaboration with leading experts in fermentation at the Centre for Process Innovation (CPI, Newcastle, UK), Algipharma has secured combined funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for pilot scale studies for production of its promising new alginate oligomer drug candidate.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2012-10-13 14:56:222023-08-09 17:05:18NANO2021 NFR Program: Norwegian Research Council Funds AlgiPharma Consortium 9.750.000 NOK for advanced wound healing applications
AlgiPharma together with FMC Biopolymer and SINTEF are part of the award winning research consortium co-ordinated by Dr. Gudmund Skjaak-Braek at the Norwegian National Biotechnology Institute (NTNU).
Khan S, Tøndervik A, Sletta H, Klinkenberg G, Emanuel C, Onsøyen E, Myrvold R, Howe RA, Walsh TR, Hill KE, Thomas DW. Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41. doi: 10.1128/AAC.00525-12. Epub 2012 Jul 23. External link to Pubmed.gov Abstract The uncontrolled, often inappropriate use of antibiotics has resulted in the increasing prevalence of antibiotic-resistant pathogens, with […]
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2012-08-26 14:53:072023-08-09 17:06:16Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2012-08-23 14:51:052023-08-09 17:06:16Philip D. Rye and Astrid Hilde Myrset joins AlgiPharma
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2011-07-25 14:49:532023-08-09 17:06:16AlgiPharma wins €4,6 million EUROSTARS grant
AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2011-04-09 14:48:312023-08-09 17:06:17AlgiPharma wins research grant from CFF
AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (Oligo-G) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2011-04-01 12:45:432023-08-09 17:06:17AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis
AlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2010-08-30 14:45:372023-08-09 17:06:17US Department of Defense supports an AlgiPharma initiated in vivo wound healing study on OligoG
Oligo-G CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2010-01-05 10:42:232023-08-09 17:06:18AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases
A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2009-09-06 09:05:142023-08-09 17:06:18AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis
The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2008-06-03 16:38:272023-08-09 17:06:19AlgiPharma wins NFR funding for basic research projects on biofilms
AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2007-09-11 14:37:032023-08-09 17:06:20AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment
On the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.
https://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.png00rogerhenriksenhttps://algipharma.com/wp-content/uploads/2016/03/algipharma-logo-skisse-340x156.pngrogerhenriksen2006-08-18 18:30:542023-08-09 17:06:20AlgiPharma Established
AlgiPharma Presenting at the Lipid Nanoparticle Development Europe Summit
/in NewsWe are delighted to have been invited to speak at the 2nd Lipid Nanoparticle Development Europe Summit, taking place 17-19th October 2023, in Amsterdam. With lipid nanoparticles (LNPs) moving beyond mRNA vaccines, AlgiPharma is developing its technology to improve the delivery and efficacy of LNP therapeutics. Dr. Philip Rye, Chief Scientific Officer at AlgiPharma will […]
AlgiPharma announces the appointment of Dr. Preston W. Campbell MD to the Board
/in NewsWe are extremely pleased to announce the appointment of Preston W. Campbell to the AlgiPharma Board as a non-executive Board Member. His experience and wisdom will be invaluable in guiding the AlgiPharma team and their alginate technology closer to market. Dr. Preston Campbell served at the Cystic Fibrosis Foundation for 25 years where he […]
AlgiPharma presented at Lipid Nanoparticle Summit in Boston
/in NewsAlgiPharma attended the LNP Formulation & Process Development conference in Boston, MA (17-19th April). Chief Scientific Officer Dr. Philip Rye presented AlgiPharma’s novel alginate oligosaccharide technology for overcoming inhalation barriers for LNP delivered therapeutics. His presentation highlighted the benefits and challenges associated with the inhalation delivery route, and how AlgiPharma’s technology can mediate the effective […]
AlgiPharma announces the appointment of Dr. Charles A Johnson and Mr. Mike Walters to the Board
/in NewsWe are extremely pleased to announce the appointment of two experienced and high-calibre pharmaceutical experts to the AlgiPharma Board as non-executive Board Members. Their combined expertise will be invaluable in bringing AlgiPharma’s alginate technology closer to market. Dr Charles Johnson is an independent consultant with over 30 years’ experience in the biotechnology industry. He gained […]
AlgiPharma Welcomes a New Member to the Team
/in NewsAlgiPharma welcomes Mr Ole Tobias Fevang to the AlgiPharma team as accounting manager in support of the Norwegian operations. He has a master’s degree in finance from BI Norwegian Business School. He has previously worked at Norwegian banks (DNB Bank AS and Sparebanken Øst), and more recently four years as an accountant at the international […]
AlgiPharma Attends the LNP Summit Congress in London
/in NewsAlgiPharma attends and presents data on its alginate oligosaccharide technology platform at the Lipid Nanoparticles Development Summit 18th-20th October in London. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the […]
AlgiPharma Adds to its Intellectual Property Portfolio
/in NewsAlgiPharma was recently granted patent protection for its United States Patent No. 11413306 (15/766272) National Phase of PCT Application PCT/EP2016/073931 for “Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract”. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded […]
AlgiPharma Attends Annual European Cystic Fibrosis Congress in Rotterdam
/in NewsAlgiPharma attends the annual ECFS congress in Rotterdam, continuing to support and learn about new developments for the treatment of people with Cystic Fibrosis. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of […]
AlgiPharma Adds to its Intellectual Property Portfolio
/in NewsAlgiPharma was recently granted patent protection in its ongoing National Phase of PCT Application PCT/EP2017/076926 for “Bacitracin-alginate oligomer conjugates”. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the […]
AlgiPharma Adds to its Intellectual Property Portfolio
/in NewsAlgiPharma was recently granted patent protection for its European Patent No. 3528830 (17791037.9) Polymyxin-alginate oligomer conjugates. This adds to AlgiPharma’s growing patent portfolio. About AlgiPharma AS: AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology […]
AlgiPharma Study Published on Potentiation of Colistin.
/in NewsAlgiPharma’s collaboration partners in Cardiff University have recently published an article on the potentiating effects of AlgiPharma’s alginate oligosaccharide technology: Stokniene J, Varache M, Rye PD, Hill KE, Thomas DW, Ferguson EL. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Sci Rep. 2022 Mar 23;12(1):4986. doi: 10.1038/s41598-022-08927-1. PMID: 35322119; PMCID: […]
AlgiPharma Phase 2 Burkholderia Study Published.
/in NewsAlgiPharma in collaboration with its clinical trials team for the randomized clinical trial NCT02453789 in CF has recently been published: Fischer R, Schwarz C, Weiser R, Mahenthiralingam E, Smerud K, Meland N, Flaten H, Rye PD. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection. J Cyst Fibros. […]
AlgiPharma in the News: GlobalNewswire and DelveInsight’s Business Report.
/in NewsJanuary 27th 2022 AlgiPharma was featured in DelveInsights’s “Cystic Fibrosis Pipeline Insight, 2022” report that provides insight on company and pipeline activities in the Cystic Fibrosis therapeutics landscape. The report highlights around 60+ products under development by companies working on novel opportunities that could influence Cystic Fibrosis treatment. The report provides insights into different therapeutic […]
AlgiPharma secures 22 MNOK in non-dilutive funding for development of its antimicrobial alginate oligosaccharide technology, with the goal to enhance fighting multidrug resistance.
/in Awards, NewsAlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Councils Innovation Project for the Industrial Sector program for the project “Therapeutic Alginates for Resistant and Recurrent Infections: Generating Eradication Therapies (TARRGET)”. The project grant awarded from the Research Council combined with the Norwegian government tax incentive scheme (SkatteFUNN) results in a […]
AlgiPharma awarded 16 MNOK grant from the Norwegian Research Council’s Innovation Project for the Industrial Sector program.
/in Awards, NewsAlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Council.
AlgiPharma is Recruiting – Again!
/in NewsDirector Clinical Research / Chief Medical Officer AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. The deadline for applications is the 24th May 2020 (see links below for further details). More details can be found at: – www.borka.no/jobb/director-clinical-research-chief-medical-officer/ – www.finn.no/177948590 – www.linkedin.com/groups/2085624 – […]
New parent company in the AlgiPharma group
/in NewsAlgiPharma AS acquired by AlgiPharma AB On December 20, 2019 the Swedish AlgiPharma AB finalized the acquisition of the Norwegian AlgiPharma AS. All shareholders in AlgiPharma AS accepted the offer from AlgiPharma AB which means that the shareholders have the same number of shares and ownership percentage in the new parent company AlgiPharma AB as […]
AlgiPharma appoints new CFO
/in NewsAlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO) Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish […]
AlgiPharma is Recruiting
/in NewsAlgiPharma announces two new positions avaliable. AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway. The deadline for applications is the 12th May 2019 […]
New 2b Clinical Trial started in Australia
/in News, Phase 2New Phase 2b Clinical Trial: A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205) A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th […]
AlgiPharma Appoints Director for Australian Operations
/in NewsAlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand. About Cystic Fibrosis: Cystic […]
Innovation Award Winner for 2018
/in Awards, NewsAlgiPharma registers new company in Australia
/in NewsAlgiPharma has registered a new proprietary limited company in Melbourne, Australia.
AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme
/in Awards, NewsAn EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.
AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)
/in Awards, NewsAlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.
AlgiPharma awarded 4 year grant from the Norwegian Research Council’s NANO2021 programme
/in Awards, NewsAlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.
Hilde Morris joins AlgiPharma
/in NewsHilde Morris has recently been appointed to replace our outgoing clinical director.
AlgiPharma collaboration with Cardiff University wins Medical Innovation Award
/in Awards, NewsAlgiPharma collaboration wins Cardiff University’s prestigious Medical Innovation Award
AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG
/in Awards, NewsAlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG.
AlgiPharma features in CFF drug development pipeline
/in NewsAlgiPharma now features on the Cystic Fibrosis Foundation (CFF) drug development pipeline
AlgiPharma signs new license agreement with NTNU
/in NewsAlgiPharma secures new license agreement with NTNU for exclusive global rights.
AlgiPharma granted Orphan Drug designation by FDA
/in NewsAlgiPharma granted Orphan Drug designation by FDA
AlgiPharma starts two new Phase 2b trials in Cystic Fibrosis
/in News, Phase 2AlgiPharma has started preparations for two new clinical phase 2b trials in cystic fibrosis patients.
AlgiPharma awarded four year grant from Norwegian Research Council
/in Awards, NewsAlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”.
Technology Strategy Board (Innovate UK) & Innovation Norway – New Funding Success
/in Awards, NewsBuilding on the previous success with the AlgiFerm project, AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), FMC Biopolymer, and SINTEF have secured additional funding from the UK’s Technology Strategy Board (now Innovate UK) and Innovation Norway for further investigation on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. The study will focus on developing methods for scaling-up microbial fermentation production of OligoG at CPI.
Technology Strategy Board & Innovation Norway – Algiferm Project Success
/in NewsThe collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has been successful in achieving the project milestones.
AlgiPharma awarded four year grant from Norwegian Research Council
/in Awards, NewsAlgiPharma has been awarded a four year grant from the Norwegian Research Council for the project “Tailored OligoG in the treatment of chronic infectious biofilms”.
Technology Strategy Board & Innovation Norway – New Funding Success
/in Awards, NewsA collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has secured funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for a feasibility study on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG.
The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms
/in Abstract, NewsPowell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, Onsøyen E, Myrvold R, Hill KE, Thomas DW. Biofouling. 2013 Apr;29(4):413-21. doi: 10.1080/08927014.2013.777954. External link to Pubmed.gov Abstract The influence of a novel, safe antibiofilm therapy on the mechanical properties of Pseudomonas aeruginosa and Acinetobacter baumannii biofilms in vitro was characterized. A multiscale approach employing […]
AlgiPharma awarded secured 2.700.000 NOK for joint UK/Norwegian innovation project
/in Awards, NewsIn collaboration with leading experts in fermentation at the Centre for Process Innovation (CPI, Newcastle, UK), Algipharma has secured combined funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for pilot scale studies for production of its promising new alginate oligomer drug candidate.
NANO2021 NFR Program: Norwegian Research Council Funds AlgiPharma Consortium 9.750.000 NOK for advanced wound healing applications
/in Awards, NewsAlgiPharma is part of a multi-disciplinary consortium that has been awarded funding from the Research Council of Norway (NANO2021 programme).
BIOTEK 2021 Funding Success 4.000.000 NOK
/in Awards, NewsAlgiPharma together with FMC Biopolymer and SINTEF are part of the award winning research consortium co-ordinated by Dr. Gudmund Skjaak-Braek at the Norwegian National Biotechnology Institute (NTNU).
Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics
/in Abstract, NewsKhan S, Tøndervik A, Sletta H, Klinkenberg G, Emanuel C, Onsøyen E, Myrvold R, Howe RA, Walsh TR, Hill KE, Thomas DW. Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41. doi: 10.1128/AAC.00525-12. Epub 2012 Jul 23. External link to Pubmed.gov Abstract The uncontrolled, often inappropriate use of antibiotics has resulted in the increasing prevalence of antibiotic-resistant pathogens, with […]
Philip D. Rye and Astrid Hilde Myrset joins AlgiPharma
/in NewsPhilip Rye (1962) came to AlgiPharma in 2012. Astrid Hilde Myrset (1956) is a biochemist by training, and joined AlgiPharma in 2012.
AlgiPharma wins €4,6 million EUROSTARS grant
/in Awards, NewsAlgiPharma has together with partners Smerud Medical Research and Simbec Research been awarded a EUROSTARS grant for a €4,6 million project.
AlgiPharma wins research grant from CFF
/in Awards, NewsAlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine.
AlgiPharma granted permission to start Phase II trials in Cystic Fibrosis
/in News, Phase 2AlgiPharma has been granted permission to start its clinical phase 2 trial in cystic fibrosis patients by the Irish Medicines Board. The study title is: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (Oligo-G) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa.
US Department of Defense supports an AlgiPharma initiated in vivo wound healing study on OligoG
/in NewsAlgiPharma has together with Prof. Chandan Sen, at Ohio State University embarked on a study to investigate the effects of OligoG in a unique biofilm infected in vivo wound healing model.
AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases
/in News, Phase 1Oligo-G CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.
AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis
/in News, Phase 1A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.
AlgiPharma wins NFR funding for basic research projects on biofilms
/in Awards, NewsThe Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.
AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment
/in NewsAlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.
AlgiPharma Established
/in NewsOn the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.